Renaissance Capital logo

VYNE News

Biotechs take the podium with the year's 3 best IPOs

VYNE Therapeutics (Menlo Tx) logo

Biotechs hold gold, silver and bronze in the 2018 IPO market. Cancer immunotherapy devloper ARMO BioSciences (ARMO) is by far the year's best-performing IPO, up 200% from its offer price. Rounding out the podium is chronic itch biotech...read more

US IPO Week Ahead: Look for a wave of filings in a quiet holiday week with 2 IPOs

AJAX

Two small deals are on the calendar for the holiday week ahead, including single-asset Reg A+ IPO Aspen REIT and blank check company Crescent Funding. We expect IPO filing activity to pick up as we move...read more

Anti-itch biotech Menlo Therapeutics prices IPO at $17, the high end of the range

VYNE Therapeutics (Menlo Tx) logo

Menlo Therapeutics, which is developing treatments for moderate to severe skin itch and chronic cough, raised $119 million by offering 7 million shares at $17, the high end of the range of $16 to $17. Menlo Therapeutics plans to list on the Nasdaq under the...read more